Fuji Pharma

Basic Information

Stock Code
4554
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
April 1965
Listing Year
June 1995
Official Website
https://www.fujipharma.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Win P, Towa Pharmaceutical, Zeria Pharmaceutical, Sawai Group Holdings, Denyo

Overview

Fuji Pharma is a pharmaceutical company founded in 1965 that has established a solid position in the industry through the manufacture and sale of generic drugs, infertility treatment agents, and contrast agents.

Current Situation

Fuji Pharma recorded consolidated net sales of approximately 36.3 billion yen and operating profit of approximately 4.2 billion yen in the fiscal year ended September 2019, possessing a stable revenue base. Its main business is generic drugs, boasting high market share in infertility treatment drugs and X-ray diagnostic vascular contrast agents. In terms of technology development, it has acquired manufacturing and marketing rights for hormone injections and contrast agents, aiming to diversify its pharmaceuticals. As part of its sustainability efforts, it focuses on reducing environmental impact in manufacturing processes and ensuring appropriate pharmaceutical supply. Through a capital and business alliance with Mitsui & Co., it is strengthening international expansion, positioning the advancement of drug discovery technology and overseas market growth as key strategies. It is advancing new business development through enhanced collaboration with related companies and competitors. In recent years, it has been characterized by active expansion of its product portfolio, including sales agreements for dysmenorrhea treatment drugs and acquisition of new approved products.

Trivia

Interesting Facts

  • A long-established pharmaceutical manufacturer developed from Fuji Yakuhin Shokai founded in 1954.
  • Holds a strong position in the infertility treatment agent segment among generic drugs.
  • Maintains a strategic partnership with Mitsui & Co., which holds 22% stake.
  • Dysmenorrhea treatment drug 'Lunabel' is one of the company's core products.
  • Toyama Prefecture factory is known as a base for high-quality pharmaceutical manufacturing.
  • Focuses on developing sustainable manufacturing processes internally.
  • Listed on the Tokyo Stock Exchange Prime Market in July 2012.
  • Consolidated employee count of approximately 1,500, mid-sized pharmaceutical manufacturer scale.
  • Long experience in the medical generic pharmaceuticals industry.
  • Possesses an abundant lineup of hormone injections.
  • Has obtained manufacturing and marketing approval for endometriosis treatment drugs.
  • Highly evaluated by medical sites for safety and quality of X-ray contrast agents.
  • In-house quality management system is top-class domestically.
  • Competes in the market with competitors like Sawai Group and Towa Pharmaceutical.
  • Pharmaceutical R&D division actively introducing AI technology.

Hidden Connections

  • Accelerating overseas business expansion through capital alliance with Mitsui & Co.
  • Has a relationship with Nobel Pharma in endometriosis treatment drug manufacturing.
  • Toyama Prefecture factory features advanced equipment meeting international quality standards.
  • Uniquely handles many hormone injections in the generic drug industry.
  • Deploys differentiation strategy using patents in the medical contrast agent field.
  • An advanced company utilizing AI and cloud for in-house quality management.
  • Has multiple track records of introducing treatments in the dysmenorrhea field.
  • Research institute and factory concentrated in Toyama City's Mizuhashi, closely collaborating.

Future Outlook

Growth Drivers

  • Continued expansion of the domestic generic drug market.
  • Accelerated overseas market development through collaboration with Mitsui & Co.
  • Expansion of new entries into off-patent biologics.
  • New product development responding to medical site needs.
  • Improved R&D efficiency through AI and digital technology utilization.
  • Increasing pharmaceutical demand in response to aging society.
  • Strengthened cost competitiveness through environmentally friendly manufacturing technology.
  • Competitive edge in the generic drug market.
  • Building product portfolio responding to diversifying medical needs.
  • Improved evaluation through business management considering sustainability.
  • Pursuit and introduction of body-friendly pharmaceutical manufacturing technology.
  • Expansion and quality enhancement of clinical testing reagent manufacturing.

Strategic Goals

  • Achieve annual net sales exceeding 50 billion yen.
  • Expand overseas sales ratio to over 20%.
  • Maintain top domestic share in off-patent drugs.
  • Build manufacturing processes with significant environmental impact reduction.
  • Establish new drug R&D system utilizing AI.
  • Continuously maintain high-quality and safe pharmaceutical supply system.
  • Double the generic drug product lineup.
  • Strengthen sustainable contributions to local communities.
  • Deepen product development in collaboration with medical sites.
  • Strengthen sales through digital platforms.

Business Segments

Medical Pharmaceutical Manufacturing

Overview
Manufactures reliable pharmaceuticals for medical institutions and strives for stable supply.
Competitiveness
Product quality assurance and diverse pharmaceutical lineup
Customers
  • Hospitals
  • Dispensing pharmacies
  • Medical wholesalers
  • Pharmaceutical exporters
  • Medical device manufacturers
Products
  • Generic drugs
  • Hormone injections
  • Contrast agents
  • Topical drugs
  • Dysmenorrhea treatment drugs
  • Allergy treatment drugs

Pharmaceutical Import and Sales

Overview
Acquires import and sales rights for domestically unapproved drugs and provides a wide range of products.
Competitiveness
Rapid introduction of overseas products and strengthened sales network
Customers
  • Pharmaceutical companies
  • Sales agents
  • Domestic distributors
Products
  • Overseas hormone injection preparations
  • Off-patent biologics
  • New generic drugs

R&D Support

Overview
Provides materials and technologies to support pharmaceutical R&D.
Competitiveness
Supply of high-purity materials for R&D
Customers
  • Universities
  • Pharmaceutical research institutions
  • Pharmaceutical companies
Products
  • Bulk drugs for clinical trials
  • Research intermediates
  • Technology licenses

OEM Pharmaceutical Manufacturing

Overview
Provides contract manufacturing services for other companies' branded pharmaceuticals.
Competitiveness
High quality control and production technology
Customers
  • Overseas pharmaceutical companies
  • Domestic generic manufacturers
Products
  • Generic drug manufacturing
  • Hormone preparation manufacturing

International Logistics and Distribution Management

Overview
Realizes product logistics with appropriate temperature control.
Competitiveness
Expertise in pharmaceutical-specific storage and transportation
Customers
  • Pharmaceutical wholesalers
  • Overseas sales agents
Products
  • Pharmaceutical transportation
  • Refrigerated storage services

Health-Related Product Sales

Overview
Also handles distribution of health-related products other than pharmaceuticals.
Competitiveness
Product development leveraging pharmaceutical knowledge
Customers
  • Drugstore chains
  • Health food manufacturers
Products
  • Vitamin preparations
  • Health supplements

Formulation Technology Provision

Overview
Provides formulation technologies and conducts joint development.
Competitiveness
Expertise in high-quality formulation technologies
Customers
  • Pharmaceutical companies
  • Research institutions
Products
  • New formulation technologies
  • Injection technologies

Quality Management Services

Overview
Provides analysis and testing necessary for pharmaceutical quality assurance.
Competitiveness
Strict and rapid quality check system
Customers
  • Pharmaceutical companies
  • Contract manufacturers
Products
  • Analytical technologies
  • Quality evaluation

Pharmaceutical Raw Material Manufacturing

Overview
Handles manufacturing and supply of raw materials for pharmaceuticals.
Competitiveness
Stable supply system and high-purity products
Customers
  • Pharmaceutical manufacturers
  • Healthcare companies
Products
  • Pharmaceutical intermediates
  • Active ingredients

Environmental Compliance Support Business

Overview
Supports reduction of environmental impact related to pharmaceutical manufacturing.
Competitiveness
Environmentally considerate manufacturing technology and consulting
Customers
  • Pharmaceutical companies
  • Medical institutions
Products
  • Environmental impact reduction technologies
  • Waste disposal services

Clinical Testing Reagent Provision

Overview
Supplies agents and reagents used in clinical testing.
Competitiveness
High-purity and safe reagent manufacturing
Customers
  • Hospital laboratories
  • Research institutions
Products
  • Contrast agents
  • Testing reagents

Medical Information Provision Services

Overview
Supports medical sites by providing accurate product information.
Competitiveness
Rapid provision of the latest pharmaceutical information
Customers
  • Physicians
  • Pharmacists
Products
  • Pharmaceutical information
  • Treatment drug guides

Competitive Advantage

Strengths

  • Long track record in generic drug manufacturing
  • Stable quality management system
  • Ownership of manufacturing and marketing rights for key hormone agents
  • Diverse pharmaceutical lineup
  • Strengthened international expansion through capital and business alliances
  • Solid management foundation and profitability
  • Broad medical institution network
  • Technological capabilities in R&D
  • Rapid product approval acquisition ability
  • Specialized and focused business areas
  • Reliable contrast agent products
  • Experienced management team
  • High regulatory compliance capability
  • Sound financial position
  • Corporate culture emphasizing social responsibility

Competitive Advantages

  • Established position and brand power in the generic drug market
  • One of the few companies holding rights for hormone injections
  • Stable procurement and sales channel expansion through alliance with Mitsui & Co.
  • Market risk diversification through abundant product portfolio
  • High specialized technology and reliability in medical contrast agent field
  • Product safety through rigorous quality control in pharmaceutical manufacturing processes
  • Fast product development speed due to specialized R&D system
  • Maintaining price competitiveness in response to drug price revisions
  • Differentiation through sustainable manufacturing and environmental measures
  • Preparedness to respond quickly to domestic and international regulations
  • Rapid market entry capability for off-patent drugs
  • Ensuring continuous revenue through stable customer base
  • Building strong trust relationships with medical sites
  • Quality maintenance through concentrated domestic manufacturing bases
  • Market expansion utilizing diverse sales channels

Threats

  • Intense price competition in the generic drug market
  • Decline in pharmaceutical demand due to domestic population decrease
  • Risk of increased entry by competitors due to patent expirations
  • Impact of regulatory strengthening and drug price revisions
  • Cost increases due to fluctuations in raw material prices
  • Political and economic instability in overseas markets
  • Decline in competitiveness due to delays in technological innovation
  • Risk to production bases from natural disasters
  • Revenue instability due to exchange rate fluctuations
  • Decline in operational efficiency due to delays in rapid DX response
  • Risk of supply chain disruptions
  • Intensified competition due to market expansion by new entrants

Innovations

2024: Obtained manufacturing and marketing approval for dysmenorrhea treatment drug 'Lunabel ULD'

Overview
Secured approval as a new treatment drug for dysmenorrhea, aiming for market expansion.
Impact
Contributes to market share expansion and new customer acquisition

2023: Acquired manufacturing and marketing rights for off-patent biologics

Overview
Entering the growing field of off-patent biologics to promote business diversification.
Impact
Contributes to annual sales growth and strengthened competitiveness

2022: Introduced environmental impact reduction technology in manufacturing processes

Overview
Adopted energy-saving and waste reduction technologies in pharmaceutical factories.
Impact
Achieved CO2 emission reductions and cost savings

2021: Renewed quality management system with cloud integration

Overview
Advanced manufacturing quality management and strengthened traceability.
Impact
Enabled improved product safety and rapid issue response

2020: Introduced AI technology in generic drug development

Overview
Improved efficiency of new drug candidate exploration using AI.
Impact
Significantly shortened development period and improved research efficiency

Sustainability

  • Promotion of waste reduction activities in manufacturing processes
  • Energy efficiency improvements to reduce environmental impact
  • Establishment of sustainable raw material procurement policies
  • Regional medical support and promotion of appropriate pharmaceutical use
  • Efforts to promote employee health and diversity
  • Acquisition of environmental ISO certification and continuous improvement
  • Reduction of water usage and promotion of recycling
  • Strengthening supply chain environment through green procurement
  • Reduction of plastic use and promotion of recycling
  • Deployment of sustainable social contribution programs
  • Stable securing of clinical pharmaceutical supply
  • Enhancement of healthcare education and support activities